Xortx TherapeuticsXRTX
13F holders, Q2 2025 (June 30)6holders +4
4new positions
0sold out
1famous investor
$0.93avg. 13F price*
At the end of Q2 2025, 6 institutions reported holding Xortx Therapeutics Inc. (XRTX) in their 13F filings, up 4 from Q1 2025. 4 opened new positions and 0 sold out. The largest holders were Citadel Advisors ($36K), UBS Group AG ($19K) and National Bank of Canada ($4K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Xortx Therapeutics Inc.
- CUSIP
- 98420Q306
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $56K |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 64,181 shares bought, net +64,181 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Citadel Advisors | 0.00% | New | 38,468 | $36K |
| UBS Group AG | 0.00% | New | 20,790 | $19K |
| National Bank of Canada | 0.00% | Add +2160.9% | 3,934 | $4K |
| Royal Bank of Canada | 0.00% | New | 663 | $1K |
| Raymond James Financial Inc. | 0.00% | New | 500 | $453 |
| Clearstead Advisors, LLC | 0.00% | No change | 277 | $251 |
"% of holder's portfolio" is XRTX's weight in each manager's 13F, not the share of Xortx Therapeutics Inc. the manager owns.